NCT04302025

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2020-11-06Est. Completion: 2026-11-30

Enrollment target: 99 participants

Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States
City of Hope - Orange County Lennar Foundation Cancer Center, Irvine, California, United States
USC Norris Cancer Center, Los Angeles, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California, United States
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
UCSF Helen Diller Family CCC, San Francisco, California, United States
University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center), Aurora, Colorado, United States
Yale Cancer Center, New Haven, Connecticut, United States
MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington D.C., District of Columbia, United States
Moffitt Cancer Center, Tampa, Florida, United States
Northwestern University, Chicago, Illinois, United States

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti…

Birmingham, United StatesEst. completion Oct 1, 2029

SCLCExtensive-stage Small Cell Lung Cancer

The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide acc…

Salina, United States

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.